ORIGINAL_ARTICLE
The Usefulness of SPECT/CT in Sentinel Node Mapping of Early Stage Breast Cancer Patients Showing Negative or Equivocal Findings on Planar Scintigraphy
Objective(s): This study sought to determine the diagnostic yield of SPECT/CT in localizing axillary sentinel lymph nodes (SLNs) in early breast cancer patients where planar scintigraphy (PS) was equivocal or negative.Methods: Prospective analysis of early stage breast cancer patients with nonpalpable axillary nodes undergoing SLN localization prior to nodal sampling for axillary staging. PS findings were categorized as: Category A: non-visualization of SLN; Category B: unusual uptake location; Category C: equivocal uptake /difficult interpretation. The K-coefficient of Cohen was used to evaluate the correlation between PS and SPECT/CT results. PS and SPECT/CT images were interpreted separately, and SLN identification on each of the modalities was correlated to BMI (Body mass index) and peroperative radio guided results.Results: Between April 2015 and January 2017, 1028 early breast cancer cases underwent sentinel lymphoscintigraphy. Of total, 134 (13%) patients underwent SPECT/CT in addition to PS. All were females with mean age of 48.15 years (range: 26-82 years). Right sided in 68, left in 64 and 2 with bilateral carcinoma. By TNM classification: 49 (37%) T1, 78 (58%) T2 and 7 (5%) had DCIS/Paget’s disease. Overall SLNs were detected on both PS and SPECT/CT in 60% cases. Of category A (n=54); 35/54 (64%) SLN localized on SPECT/CT; 32 were level-I; 2 Level-II; 1 Level-III nodes. In 19, SLN was not localized. Of category B (n=18), 5 had prior lumpectomy, SPECT/CT localized tracer uptake to 17 level-I sentinel nodes, 3 level-II and level III / IMC in 9. Of category C (n=62), 29 had prior lumpectomy. SPECT/CT confirmed SLN in all the cases. Radio-guided surgery confirmed SPECT/CT results. The correlation between the two techniques was low (K=0.34). Where PS was negative; SPECT/CT localized nodes in statistically significant number of cases (P=0.01). PS identified SLN uptakes in 80/134 (60%) cases with a mean BMI of 21.6±4.8 kg/m2 while SPECT/CT detected ‘‘hot’’ nodes in 115/134 (86%) cases with a mean BMI of 29.6±5.6 kg/m2. For overweight/obese patients (n=59) (BMI>25 kg/m2), PS failed to identify SLNs in 49 and SPECT/CT failed to do so in 18 (P<0.001).Conclusion: SPECT/CT has diagnostic yield and helps in precise SLN localization where planar imaging is negative or shows unusual site of uptake.
https://aojnmb.mums.ac.ir/article_10720_0b9c7827cebfdb7a504243b3fa7a5565.pdf
2018-07-01
80
89
10.22038/aojnmb.2018.10720
Sentinel node
SPECT/CT
Planar Scintigraphy
Breast Cancer
Maimoona
Siddique
maimoona.siddique@pkli.org.pk
1
Pakistan Kidney and Liver Institute &amp; Research Centre. Lahore. Pakistan.
LEAD_AUTHOR
Muhammad
Nawaz
khalid.nawaz@pkli.org.pk
2
Pakistan Kidney and Liver Institute & Research Centre. Lahore. Pakistan
AUTHOR
Humayun
Bashir
bashir.humayun@gmail.com
3
SKMCH&RC
AUTHOR
1.Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):359-86.
1
2.Khokher S, Qureshi MU, Riaz M, Akhtar N, Saleem A. Clinicopathologic profile of breast cancer patients in Pakistan: ten years data of a local cancer hospital. Asian Pac J Cancer Prev. 2012;13(2):693-8.
2
3.yman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703-20.
3
4.Verheuvel NC, Voogd AC, Tjan-Heijnen VC, Siesling S, Roumen RM. Different outcome in node-positive breast cancer patients found by axillary ultrasound or sentinel node procedure. Breast Cancer Res Treat. 2017;165(3):555-63.
4
5.Kraft O, Havel M. Sentinel lymph nodes and planar scintigraphy and SPECT/CT in various types of tumour. Estimation of some factors influencing detection success. Nucl Med Rev Cent East Eur. 2013;16(1):17-25.
5
6.Dickinson RL, Erwin WD, Stevens DM, Bidaut LM, Mar MV, Macapinlac HA, et al. Hybrid modality fusion of planar scintigram and CT topograms to localize sentinel lymph nodes in breast lymphoscintigraphy: Technical description and phantom studies. Int J Mol Imaging. 2011;2011:298102.
6
7.Vidal-Sicart S, Valdes Olmos R. Sentinel node mapping for breast cancer: current situation. J Oncol. 012;2012:361341.
7
8.Canavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, et al. sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial. Ann Surg Oncol. 2016;23(8):2494-500.
8
9.Jimenez-Heffernan A, Ellmann A, Sado H, Huić D, Bal C, Parameswaran R, et al. Results of a prospective multicenter international atomic energy agency sentinel node trial on the value of SPECT/CT over planar imaging in various malignancies. J Nucl Med. 2015;56(9):1338-44.
9
10. Van der Ploeg IM, Valdés Olmos RA, Nieweg OE, Rutgers EJ, Kroon BB, Hoefnagel CA. The additional value of SPETCT/TC in lymphatic mapping in breast cancer and melanoma. J Nucl Med. 2007;48(11):1756-60.
10
11. Kraft O, Havel M. Sentinel lymph node identification in breast cancer–comparison of planar scintigraphy and SPECT/CT. Open Nucl Med J. 2012;4:5-13.
11
12. van der Ploeg IM, Nieweg OE, Kroon BB, Rutgers EJ, Baas-Vrancken Peeters MJ, Vogel WV, et al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2009;36(6):903-9.
12
13. Olmos RV, Rietbergen DD, Vidal-Sicart S, Manca G, Giammarile F, Mariani G. Contribution of SPECT/CT imaging to radioguided sentinel lymph node biopsy in breast cancer, melanoma, and other solid cancers: from “open and see” to “see and open”. Q J Nucl Med Mol Imaging. 2014;58:127-39.
13
14. van der Ploeg IM, Valdés Olmos RA, Kroon BB, Nieweg OE. The hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg. 2008;32(9):1930-4.
14
15. Lerman H, Lievshitz G, Zak O, Metser U, Schneebaum S, Even-Sapir E. Improved sentinel lymph node identification by SPECT/CT in overweight patients with breast cancer. J Nucl Med. 2007;48(2):201-6.
15
16. Lerman H, Metser U, Lievshitz G, Sperber F, Shneebaum S, Even-Sapir E. Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT-CT. Eur J Nucl Med Mol Imaging. 2006;33(3):329-37.
16
17. Martínez A, Zerdoud S, Mery E, Bouissou E, Ferron G, Querleu D. Hybrid imaging by SPECT/CT for sentinel lymph node detection in patients with cancer of the uterine cervix. Gynecol Oncol. 2010;119(3):431-5.
17
18. Vercellino L, Ohnona J, Groheux D, Slama A, Colletti PM, Chondrogiannis S, et al. Role of SPECT/CT in sentinel lymph node detection in patients with breast cancer. Clin Nucl Med. 2014;39(5):431-6.
18
19. U.S. breast cancer statistics. Breastcancer.org. Available at: URL: http://www.breastcancer.org/symptoms/understand_bc/statistics; 2018.
19
20. Schneebaum S, Even-Sapir E, Lerman H, Gat A, Brazovsky E, Lievshitz G. Clinical application of gamma detection probes: radio guided surgery. Eur J Nucl Med. 1999;26(1):26-35.
20
21. Cox CE, Dupont E, Whitehead GF, Ebert MD, Nguyen K, Peltz ES, et al. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002;8(2):88-91.
21
22. Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, Rasoul Zakavi S, Memar B, Naser Forghani M, et al. Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. Rev Esp Med Nucl. 2010;29(2):73-7.
22
23. Leijte JA, Van der Ploeg IM, Valdes Olmos RA, Nieweg OE, Horenblas S. Visualization of tumor blockage and rerouting of lymphatic drainage in penile cancer patients by use of SPECT/CT. J Nucl Med. 2009;50(3):364-7.
23
24. Schrenk P, Rehberger W, Shamiyeh A, Wayand W. Sentinel node biopsy for breast cancer: does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node? J Surg Oncol. 2002;80(3):130-6.
24
25. Heuser T, Rink T, Weller E, Fitz H, Zippel HH, Kreienberg R, et al. Impact of the axillary nodal status on sentinel node mapping in breast cancer and its relevance for technical proceeding. Breast Cancer Res Treat. 2001;67(2):125-32.
25
26. Lo YF, Hsueh S, Ma SY, Chen SC, Chen MF. Clinical relevance of nonvisualized sentinel lymph nodes in unselected breast cancer patients during lymphoscintigraphy. Chang Gung Med J. 2005;28(6):378-86.
26
27. Kroon BK, Valdés Olmos R, Nieweg OE, Horenblas S. Non-visualization of sentinel lymph nodes in penile carcinoma. Eur J Nucl Med Mol Imaging. 2005;32(9):1096-9.
27
28. Bennie G, Vorster M, Buscombe J, Sathekge M. The added value of a single-photon emission computed tomography: computed tomography in the sentinel lymph node mapping in patients with breast cancer and malignant melanoma. World J Nucl Med. 2015;14(1):41-6.
28
29. Husarik DB, Steinert HC. Single photon emission computed tomogrsphy/computed tomography for sentinel node mapping in breast cancer. Semin Nucl Med. 2007;37(1):29-33.
29
30. Gallowitsch HJ, Kraschl P, Igerc I, Hussein T, Kresnik E, Mikosch P, et al. Sentinel node SPECT/CT in breast cancer. Can we expect any additional and relevant clinical information? Nuklearmedizin. 2007;46(6):252-6.
30
31. Frusciante V, Niccoli A, Castriotta G, Guerra M, Murgo R, Ciuffreda L, et al. Added value of SPECT/CT over planar imaging in improving sentinel node detection in breast cancer patients. Recent Prog Med. 2016;107(8):444-9.
31
32. Keidar Z, Israel O, Krausz Y. SPECT/CT in tumor imaging: Technical aspects and clinical applications. Semin Nucl Med. 2003;33(3):205-18.
32
33. Law M, Ma WH, Leung R, Li S, Wong KK, Ho WY, et al. Evaluation of patient effective dose from sentinel lymph node lymphoscintigraphy in breast cancer: a phantom study with SPECT/CT and ICRP-103 recommendations. Eur J Radio. 2012;81(5):717-20.
33
ORIGINAL_ARTICLE
The Status of Stress Myocardial Perfusion Imaging Using 99mTc Pharmaceuticals in Japan: Results from a Nationwide Survey
Objective(s): To appropriately use one-day myocardial perfusion imaging (MPI) with 99mTc radiopharmaceuticals (i.e. to avoid shine-through artifacts), injection doses need to be optimized and dose ratios between the 1st and 2nd scans should be maintained at ≥ 3. However, the current state of practice in Japan is unclear. Thus, the aim of this study was to clarify the details of MPI protocols using 99mTc radiopharmaceuticals in Japan.Methods: A nationwide survey was conducted in June and July 2016. Questionnaires about stress MPI protocols using 99mTc radiopharmaceuticals were sent to 641 nuclear medicine facilities.Results: Responses were received from 246 facilities. One-day protocols were used in 97.1% of the facilities. The most common injection dose ratio was 2.5. Only 18.2% of facilities achieved the recommended injection dose ratio. Stress-only protocols were performed in only 1.7% of facilities; the primary reasons for not performing stress-only protocols were as follows:1) “The reading-physician cannot interpret the image just after the first scan,” and 2) “Preparation of radiopharmaceuticals and scan arrangements turn out to be complicated.”Conclusion: Approximately 80% of nuclear medicine facilities do not follow the recommended injection dose ratio. Stress-only protocols are ideal, but are performed at very few facilities. Both optimization and standardization of stress MPI protocols using 99mTc radiopharmaceuticals are needed in Japan.
https://aojnmb.mums.ac.ir/article_10477_85e84d28de92f844551f141899920660.pdf
2018-07-01
90
96
10.22038/aojnmb.2018.10477
myocardial perfusion imaging
Nuclear Medicine
SPECT
Ryoto
Otsuka
u287924k@ecs.osaka-u.ac.jp
1
Division of Health Science, Osaka University Graduate School of Medicine
AUTHOR
Yosuke
Miyazaki
miyayou07@yahoo.co.jp
2
Osaka University
AUTHOR
Narumi
Kubo
u372747d@ecs.osaka-u.ac.jp
3
Osaka University
AUTHOR
Mio
Kawahara
ponepones@yahoo.co.jp
4
Osaka University
AUTHOR
Jun
Takaesu
jun.1121.sskr@gmail.com
5
Osaka University
AUTHOR
Kazuki
Fukuchi
kfukuchi@sahs.med.osaka-u.ac.jp
6
Division of Health Science, Osaka University Graduate School of Medicine
LEAD_AUTHOR
Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, Nagel E, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. J Am Coll Cardiol. 2012;59(19):1719-28.
1
Metz LD, Beattie M, Hom R, Redberg RF, Grady D, Fleischmann KE. The prognostic value of normal exercise myocardial perfusion imaging and exercise echocardiography: a meta-analysis. J Am Coll Cardiol. 2007;49(2):227-37.
2
Dorbala S, Di Carli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol. 2013;61(2):176-84.
3
Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LE, Friedman JD, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32(8):1012-24.
4
Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117(10):1283-91.
5
Einstein A. Effects of radiation exposure from cardiac imaging: how good are the data? J Am Coll Cardiol. 2012;59(6):553-65.
6
Einstein A, Pascual TN, Mercuri M, Karthikeyan G, Vitola JV, Mahmarian JJ, et al. Current worldwide nuclear cardiology practices and radiation exposure: result from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS). Eur Heart J. 2015;36(26):1689-96.
7
Otsuka R, Kubo N, Miyazaki Y, Kawahara M, Takaesu J, Fukuchi K. Current status of stress myocardial perfusion imaging pharmaceuticals and radiation exposure in Japan: results from a nationwide survey. J Nucl Cardiol. 2017;24(6):1850-5.
8
Pascual TN, Mercuri M, El-Haj N, Bom HH, Lele V, Al-Mallah MH, et al. Nuclear cardiology practice in Asia: analysis of radiation exposure and best practice for myocardial perfusion imaging -Results from the IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS). Circ J. 2017;81(4):501-10.
9
10. Gupta A, Bajaj NS. Reducing radiation exposure from nuclear myocardial perfusion imaging: time to act is now. J Nucl Cardiol. 2017;24(6):1856-9.
10
11. Mercuri M, Pascual TN, Mahmarian JJ, Shaw LJ, Dondi M, Paez D, et al. Estimating the reduction in the radiation burden from nuclear cardiology through use of stress-only imaging in the United States and worldwide. JAMA Intern Med. 2016;176(2):269-73.
11
12. Van Train KF, Garcia EV, Maddahi J, Areeda J, Cooke CD, Kiat H, et al. Multicenter trial validation for quantitative analysis of same-day rest-stress technetium-99m-sestamibi myocardial tomograms. J Nucl Med. 1994;35(4):609-18.
12
13. Taillefer R, Gagnon A, Laflamme L, Grégoire J, Léveillé J, Phaneuf DC. Same day injections of Tc-99m methoxy isobutyl isonitrile (hexamibi) for myocardial tomographic imaging: comparison between rest–stress and stress–rest injection sequences. Eur J Nucl Med. 1989;15(3):113-7.
13
14. Van Train KF, Areeda J, Garcia EV, Cooke CD, Maddahi J, Kiat H, et al. Quantitative same-day rest-stress technetium-99m-sestamibi SPECT: definition and validation of stress normal limits and criteria for abnormality. J Nucl Med. 1993;34(9):1494-502.
14
15. Hesse B, Tägil K, Cuocolo A, Anagnostopoulos C, Bardiés M, Bax J, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging. 2005;32(7):855-97.
15
16. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016;23(3):606-39.
16
17. Taillefer R, Laflamme L, Dupras G, Picard M, Phaneuf DC, Léveillé J. Myocardial perfusion imaging with 99mTc-methoxy-isobutyl-isonitrile (MIBI): comparison of short and long time intervals between rest and stress injections. Preliminary results. Eur J Nucl Med. 1988;13(10):515-22.
17
18. Thompson RC, O’Keefe JH, McGhie AI, Bybee KA, Thompson EC, Bateman TM. Reduction of SPECT MPI radiation dose using contemporary protocols and technology. JACC Cardiovasc Imaging. 2017;11(2 Pt 1):282-3.
18
19. Nakajima K, Okuda K, Momose M, Matsuo S, Kondo C, Sarai M, et al. IQ·SPECT technology and its clinical applications using multicenter normal databases. Ann Nucl Med. 2017;31(9):649-59.
19
ORIGINAL_ARTICLE
Brain Single Photon Emission Computed Tomography Scan (SPECT) and Functional MRI in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction: A Systematic Review
Objective(s): Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide range of clinical manifestations. Cognitive dysfunction is one of the manifestations that could present prior to the emergence of any other neuropsychiatric involvements in SLE. Cognitive dysfunction is a subtle condition occurring with ahigh frequency. However, there is no data on the correlation of cognitive dysfunction with central nervous system (CNS) imaging findings, in particular single-photon emission computed tomography scan (SPECT) and functional MRI. We decided to perform a systematic review of brain SPECT and fMRI in SLE patients with cognitive dysfunction.Methods: PubMed, Scopus, and Google Scholar databases were searched until April 2017 with the following keywords: “SLE OR systemic lupus erythematous OR lupus” AND “functional MRI OR functional magnetic resonance imaging OR fMRI OR SPECT or SCAN”. A total of 1,767articles were found. Two rheumatologistsreviewed the articles and finally 14 articles were selected for the final systematic review.Results: The fMRI and SPECT imaging techniques could provide valuable information regarding the SLE patients with cognitive dysfunction at the early stages of the disease.Conclusion: Brain SPECT scan and fMRI are used as functional imaging tools in SLE. Both of these diagnostic modalities are sensitive in reflecting the subtle brain damages in SLE patients with cognitive dysfunction. Brain fMRI and SPECT scan could be significantly beneficial in the diagnosis and initial management of cognitive dysfunction in SLE. Nevertheless, prospective studies could be useful in confirming the application of these diagnostic modalities in the clinical setting.
https://aojnmb.mums.ac.ir/article_10478_07165e45fffa37326206b9efbaa350b1.pdf
2018-07-01
97
107
10.22038/aojnmb.2018.26381.1184
systemic lupus erythematosus
SPECT
functional magnetic resonance imaging
cognitive dysfunction
Maryam
Sahebari
sahebarim@mums.ac.ir
1
Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Zahra
Rezaieyazdi
rezaieyazdiz@mums.ac.ir
2
Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mandana
Khodashahi
mkhodashahi53@gmail.com
3
Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Bita
Abbasi
abbasib@mums.ac.ir
4
Department of Radiology, School of Medicine, Mashhad University of Medical Sciences; Mashhad, Iran
AUTHOR
Fazlollah
Ayatollahi
kumsrescen@gmail.com
5
Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Meszaros ZS, Perl A, Faraone SV. Psychiatric symptoms in systemic lupus erythematosus: a systematic review. J Clin Psychiatry. 2012;73(7):993-1001.
1
The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42(4):599-608.
2
Peretti CS, Peretti CR, Kozora E, Papathanassiou D, Chouinard VA, Chouinard G. Cognitive impairment in systemic lupus erythematosus women with elevated autoantibodies and normal single photon emission computerized tomography. Psychother Psychosom. 2012;81(5):276-85.
3
Kozora E, Laudenslager M, Lemieux A, West SG. Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol Soc. 2001;7(6):745-54.
4
Sankowski R, Mader S, Valdes-Ferrer SI. Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28.
5
Petri M, Naqibuddin M, Carson KA, Sampedro M, Wallace DJ, Weisman MH, et al. Cognitive function in a systemic lupus erythematosus inception cohort. J Rheumatol. 2008;35(9):1776-81.
6
Lopez-Longo FJ, Carol N, Almoguera MI, Olazaran J, Alonso-Farto JC, Ortega A, et al. Cerebral hypoperfusion detected by SPECT in patients with systemic lupus erythematosus is related to clinical activity and cumulative tissue damage. Lupus. 2003;12(11):813-9.
7
Sanna G, Piga M, Terryberry JW, Peltz MT, Giagheddu S, Satta L, et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus. 2000;9(8):573-83.
8
Phillips B, Ball C, Badenoch D, Straus S, Haynes B, Dawes M. Oxford centre for evidence-based medicine levels of evidence (May 2001). BJU Int. 2011;107(5):870.
9
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
10
11. Brey R, Holliday S, Saklad A, Navarrete M, Hermosillo-Romo D, Stallworth C, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002;58(8):1214-20.
11
12. DiFrancesco MW, Holland SK, Ris MD, Adler CM, Nelson S, DelBello MP, et al. Functional magnetic resonance imaging assessment of cognitive function in childhood-onset systemic lupus erythematosus: a pilot study. Arthritis Rheum. 2007;56(12):4151-63.
12
13. Fitzgibbon B, Fairhall S, Kirk I, Kalev-Zylinska M, Pui K, Dalbeth N, et al. Functional MRI in NPSLE patients reveals increased parietal and frontal brain activation during a working memory task compared with controls. Rheumatology. 2007;47(1):50-3.
13
14. Shapira-Lichter I, Vakil E, Litinsky I, Oren N, Glikmann-Johnston Y, Caspi D, et al. Learning and memory-related brain activity dynamics are altered in systemic lupus erythematosus: a functional magnetic resonance imaging study. Lupus. 2013;22(6):562-73.
14
15. Al-Obaidi M, Saunders D, Brown S, Ramsden L, Martin N, Moraitis E, et al. Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol. 2016;35(10):2449-56.
15
16. Piga M, Peltz MT, Montaldo C, Perra D, Sanna G, Cauli A, et al. Twenty-year brain magnetic resonance imaging follow-up study in systemic lupus erythematosus: factors associated with accrual of damage and central nervous system involvement. Autoimmun Rev. 2015;14(6):510-6.
16
17. Cesar B, Dwyer MG, Shucard JL, Polak P, Bergsland N, Benedict RH, et al. Cognitive and white matter tract differences in MS and diffuse neuropsychiatric systemic lupus erythematosus. AJNR Am J Neuroradiol. 2015;36(10):1874-83.
17
18. Zimmermann N, Corrêa DG, Kubo TA, Netto TM, Pereira DB, Fonseca RP, et al. Global cognitive impairment in systemic lupus erythematosus patients: a structural MRI study. Clin Neuroradiol. 2017;27(1):23-9.
18
19. Sarbu N, Alobeidi F, Toledano P, Espinosa G, Giles I, Rahman A, et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev. 2015;14(2):153-9.
19
20. Ichinose K, Arima K, Ushigusa T, Nishino A, Nakashima Y, Suzuki T, et al. Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. Clin Immunol. 2015;157(2):114-20.
20
21. Nishimura K, Omori M, Katsumata Y, Sato E, Gono T, Kawaguchi Y, et al. Neurocognitive impairment in corticosteroid-naive patients with active systemic lupus erythematosus: a prospective study. J Rheumatol. 2015;42(3):441-8.
21
22. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, Minoshima S, et al. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2008;59(3):332-7.
22
23. Oh D, Kim S, Jung S, Sung Y, Bang S, Bae S, et al. Precuneus hypoperfusion plays an important role in memory impairment of patients with systemic lupus erythematosus. Lupus. 2011;20(8):855-60.
23
24. Zhang X, Zhu Z, Zhang F, Shu H, Li F, Dong Y. Diagnostic value of single-photon-emission computed tomography in severe central nervous system involvement of systemic lupus erythematosus: a case-control study. Arthritis Rheum. 2005;53(6):845-9.
24
25. Waterloo K, Omdal R, Sjoholm H, Koldingsnes W, Jacobsen EA, Sundsfjord JA, et al. Neuropsychological dysfunction in systemic lupus erythematosus is not associated with changes in cerebral blood flow. J Neurol. 2001;248(7):595-602.
25
26. Mackay M, Bussa MP, Aranow C, Uluğ AM, Volpe BT, Huerta PT, et al. Differences in regional brain activation patterns assessed by functional magnetic resonance imaging in patients with systemic lupus erythematosus stratified by disease duration. Mol Med. 2011;17(11-12): 1349-56.
26
27. Rocca MA, Agosta F, Mezzapesa DM, Ciboddo G, Falini A, Comi G, et al. An fMRI study of the motor system in patients with neuropsychiatric systemic lupus erythematosus. Neuroimage. 2006;30(2):478-84.
27
28. Maeshima E, Yamada Y, Yukawa S, Nomoto H. Higher cortical dysfunction, antiphospholipid antibodies and neuroradiological examinations in systemic lupus erythematosus. Intern Med. 1992;31(10):1169-74.
28
29. Kao CH, Ho YJ, Lan JL, Changlai SP, Liao KK, Chieng PU. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum. 1999;42(1):61-8.
29
30. Sun SS, Huang WS, Chen JJ, Chang CP, Kao CH, Wang JJ. Evaluation of the effects of methylprednisolone pulse therapy in patients with systemic lupus erythematosus with brain involvement by Tc-99m HMPAO brain SPECT. Eur Radiol. 2004;14(7): 1311-5.
30
31. Liu FY, Huang WS, Kao CH, Yen RF, Wang JJ, Ho ST. Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report. Rheumatol Int. 2003;23(4):182-5.
31
32. Castellino G, Padovan M, Bortoluzzi A, Borrelli M, Feggi L, Caniatti ML, et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology. 2008;47(3):319-23.
32
33. Strakowski SM, Adler CM, Holland SK, Mills N, DelBello MP. A preliminary FMRI study of sustained attention in euthymic, unmedicated bipolar disorder. Neuropsychopharmacology. 2004;29(9):1734-40.
33
34. McKiernan KA, D’Angelo BR, Kaufman JN, Binder JR. Interrupting the “stream of consciousness”: an fMRI investigation. Neuroimage. 2006;29(4): 1185-91.
34
35. Weinberger DR, Mattay V, Callicott J, Kotrla K, Santha A, van Gelderen P, et al. fMRI applications in schizophrenia research. Neuroimage. 1996;4(3 Pt 3):S118-26.
35
36. Chen JJ, Yen RF, Kao A, Lin CC, Lee CC. Abnormal regional cerebral blood flow found by technetium-99m ethyl cysteinate dimer brain single photon emission computed tomography in systemic lupus erythematosus patients with normal brain MRI findings. Clin Rheumatol. 2002;21(6):516-9.
36
37. Lin WY, Wang SJ, Yen TC, Lan JL. Technetium-99m-HMPAO brain SPECT in systemic lupus erythematosus with CNS involvement. J Nucl Med. 1997;38(7):1112-5.
37
ORIGINAL_ARTICLE
Comparison of Treatment Response Achieved by Tablet Splitting Versus Whole Tablet Administration of Levothyroxine in Patients with Thyroid Cancer
Objective(s): TSH suppression by Levothyroxine consumption is a mainstay of thyroid cancer treatment. Tablet-splitting is a worldwide approach in dose adjustment in patients. However, it is highly recommended to evaluate the validity of tablet splitting for each distinctive drug by clinical trials before routinely using tablet halves in clinical practice. In this study we compared the effect of 150 μg dose of Levothyroxine by use of a100 and a 50 μg tablets or one and half 100 μg tablets in Differentiated thyroid cancer (DTC) patients.Methods: One hundred DTC patients treated with one and half 100 μg Levothyroxine tablets were randomly divided into two groups. The first group continued taking medication as before and the second group received the same daily dose by taking one 100 and one 50 microgram Levothyroxine tablets. The mean changes in TSH and T3 levels and patients weight were compared between the groups.Results: 91 patients completed the study. Levothyroxine consumption pattern, age, gender distribution, weight and TSH levels were comparable between groups at the beginning of the study. The mean change of body weights, serum levels of T3 and TSH showed no significant difference between groups in different time points during the study (P>0.05).Conclusion: This study showed similar efficacy of tablet splitting and two tablets administration for Levothyroxine; however, patients preferred two tablets at the end of the study. It can be concluded that tablet splitting can be used as an alternative way when the 50 μg tablet is not available.
https://aojnmb.mums.ac.ir/article_10347_051f55cd46fb23cca724b0ba937e7334.pdf
2018-07-01
108
112
10.22038/aojnmb.2018.26793.1187
Tablet splitting
Differentiated thyroid cancer, TSH, Levothyroxine, suppressive therapy
Ramin
Ashrafpour
ramin.ashrafpour@gmail.com
1
School of medicine, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Narjess
Ayati
ayatin@mums.ac.ir
2
Nuclear Medicine Research Center, Mashhad University of Medical Science
LEAD_AUTHOR
Ramin
Sadeghi
sadeghir@mums.ac.ir
3
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Samira
Zare Namdar
zarens2@mums.ac.ir
4
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Nayyereh
Ayati
ayatin881@mums.ac.ir
5
Department of pharmacoeconomics and pharmaceutical administration, faculty of pharmacy, Tehran University of medical sciences, Tehran, Iran
AUTHOR
Somaye
Ghahremani
ghahremanis931@mums.ac.ir
6
nuclear medicine research center, ghaem hospital,mashhad,iran
AUTHOR
Seyed Rasoul
Zakavi
zakavir@mums.ac.ir
7
Nuclear Medicine Research Center, Mashhad University of Medical Sciences
AUTHOR
Zakavi SR, Ayati N, Farahati J, Davachi B. Diffuse skeletal metastasis and low thyroglobulin level in a pediatric patient with papillary thyroid carcinoma. Indian J Nucl Med. 2015;30(3):283-5.
1
Zakavi SR. Meta-analysis on successful ablation after low- versus high-dose radioiodine therapy in patients with differentiated thyroid carcinoma. Clin Nucl Med. 2016;41(8):674.
2
Haugen BR. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017; 123(3):372-81.
3
Freeman MK, White W, Iranikhah M. Tablet splitting: a review of the clinical and economic outcomes and patient acceptance. Second of a 2-part series. Part 1 was published in May 2012 (Consult Pharm 2012;27:239-53). Consult Pharm. 2012;27(6):421-30.
4
Elliott I, Mayxay M, Yeuichaixong S, Lee SJ, Newton PN. The practice and clinical implications of tablet splitting in international health. Trop Med Int Health. 2014; 19(7):754-60.
5
Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M. Tablet-splitting: a common yet not so innocent practice. J Adv Nurs. 2011;67(1):26-32.
6
Tablet splitting. JAMA. 2014;311(5):521.
7
Chou CL, Hsu CC, Chou CY, Chen TJ, Chou LF, Chou YC. Tablet splitting of narrow therapeutic index drugs: a nationwide survey in Taiwan. Int J Clin Pharm. 2015;37(6):1235-41.
8
Tahaineh LM, Gharaibeh SF. Tablet splitting and weight uniformity of half-tablets of 4 medications in pharmacy practice. J Pharm Pract. 2012;25(4):471-6.
9
10. Dormuth CR, Schneeweiss S, Brookhart AM, Carney G, Bassett K, Adams S, et al. Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis. Open Med. 2008;2(3):e74-82.
10
11. Vranic E, Uzunovic A. Influence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets. Bosn J Basic Med Sci. 2007;7(4):328-34.
11
12. Cook TJ, Edwards S, Gyemah C, Shah M, Shah I, Fox T. Variability in tablet fragment weights when splitting unscored cyclobenzaprine 10 mg tablets. J Am Pharm Assoc. 2004;44(5):583-6.
12
13. Zhao N, Zidan A, Tawakkul M, Sayeed VA, Khan M. Tablet splitting: product quality assessment of metoprolol succinate extended release tablets. Int J Pharm. 2010;401(1-2):25-31.
13
14. Nidanapu RP, Rajan S, Mahadevan S, Gitanjali B. Tablet splitting of antiepileptic drugs in pediatric epilepsy: potential effect on plasma drug concentrations. Paediatr Drugs. 2016;18(6):451-63.
14
15. Abu-Geras D, Hadziomerovic D, Leau A, Khan RN, Gudka S, Locher C, et al. Accuracy of tablet splitting and liquid measurements: an examination of who, what and how. J Pharm Pharmacol. 2017;69(5):603-12.
15
16. Mascarenhas Starling F, Medeiros-Souza P, Francisco de Camargos E, Ferreira F, Rodrigues Silva A, Homem-de-Mello M. Tablet splitting of psychotropic drugs for patients with dementia: a pharmacoepidemiologic study in a Brazilian sample. Clin Ther. 2015;37(10):2332-8.
16
17. Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol. 2006;62(12):1065-73.
17
18. Tablet splitting: evaluating appropriateness for patients. J Am Pharm Assoc. 2004;44(3):324-5.
18
19. Peek BT, Al-Achi A, Coombs SJ. Accuracy of tablet splitting by elderly patients. JAMA. 2002;288(4): 451-2.
19
20. Shah RB, Collier JS, Sayeed VA, Bryant A, Habib MJ, Khan MA. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS PharmSciTech. 2010;11(3):1359-67.
20
21. Helmy SA. Tablet splitting: is it worthwhile? Analysis of drug content and weight uniformity for half tablets of 16 commonly used medications in the outpatient setting. J Manag Care Spec Pharm. 2015;21(1):76-86.
21
22. Freeman MK, White W, Iranikhah M. Tablet splitting: a review of weight and content uniformity. Consult Pharm. 2012;27(5):341-52.
22
23. McDevitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting. Pharmacotherapy. 1998;18(1):193-7.
23
24. Zakavi SR, Zare NS, Shafiei S, Sadeghi R, Fekri N, Mazloum KZ, et al. Which complaint has the most clinical effect on quality of life of thyroid cancer survivors in long term follow up? Iran J Nucl Med. 2015;23(1):21-6.
24
25. Vuchetich PJ, Garis RI, Jorgensen AM. Evaluation of cost savings to a state Medicaid program following a sertraline tablet-splitting program. J Am Pharm Assoc. 2003;43(4):497-502.
25
26. Curtiss FR. Tablet splitting to improve the value-for-money equation in cholesterol management. J Manag Care Pharm. 2002;8(6):519.
26
27. Fawell NG, Cookson TL, Scranton SS. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance. Am J Health Syst Pharm. 1999;56(24):2542-5.
27
ORIGINAL_ARTICLE
A comparison of 2D and 3D kidney absorbed dose measures in patients receiving 177Lu-DOTATATE
Objective(s): To investigate and compare quantitative accuracy of kidney absorbed dose measures made from both 2D and 3D imaging in patients receiving 177LuDOTATATE (Lutate) for treatment of neuroendocrine tumours (NETs). Methods: Patients receiving Lutate therapy underwent both whole body planar imaging and SPECT/CT imaging over the kidneys at time points 0.5, 4, 24, and 96-120 hours after injection. Planar data were corrected for attenuation using transmission data, and were converted to units of absolute activity via two methods, using either a calibration standard in the field of view or relative to pre-voiding image total counts. Hand drawn regions of interest were used to generate time activity curves and kidney absorbed dose estimates in OLINDA-EXM. Fully quantitative SPECT data were generated using CT-derived corrections for both scatter and attenuation, before correction for dead time and application of a camera specific sensitivity factor to convert data to units of absolute activity. Volumes of interest were defined for kidney using the co-registered x-ray CT, before time activity curves and absorbed dose measures were generated in OLINDA-EXM, both with and without corrections made to the model for patient specific kidney volumes. Quantitative SPECT data were also used to derive dose maps through dose kernel convolution (DKC), which was treated as the gold standard. Results: A total of 50 studies were analysed, corresponding to various cycles of treatment from 21 patients. Planar absorbed dose estimates were consistently higher than SPECT derived estimates by, on average, a factor of 3. Conclusion: Quantitative SPECT is considered the gold standard approach for organ specific dosimetry however often relies on in house software. As such planar methods for estimating absorbed dose are much more widely available, and in particular, are often the only source of reference in previously published data. For the case of Lutate dosimetry, planar measures may lead to a three-fold increase in measures of kidney absorbed dose.
https://aojnmb.mums.ac.ir/article_10329_444f4ef7f5a36d93b731d54a47988a6a.pdf
2018-07-01
113
119
10.22038/aojnmb.2018.26105.1182
Lutate
Dosimetry
Kidney
NET
Kathy
Willowson
kathy.willowson@sydney.edu.au
1
Institute of Medical Physics, The University of Sydney
LEAD_AUTHOR
HyunJu
Ryu
hryu0789@uni.esydney.edu.au
2
Faculty of Health Sciences, University of Sydney, Lidcombe 2141, Australia
AUTHOR
Price
Jackson
price.jackson@petermac.org
3
Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne 3000, VIC, Australia
AUTHOR
Enid
Eslick
enid.eslick@sydney.edu.au
4
Institute of Medical Physics, School of Physics, University of Sydney, 2006 NSW, Australia
AUTHOR
Anita
Singh
anita_spk@yahoo.com.au
5
Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards 2065, NSW, Australia
AUTHOR
Dale
Bailey
dale.bailey@sydney.edu.au
6
Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards 2065, NSW, Australia Faculty of Health Sciences, University of Sydney, Lidcombe 2141, Australia
AUTHOR
Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe(1)-Tyr(3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37(2):212-25.
1
Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med. 2005;46:83S-91.
2
Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467-75.
3
Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109-22.
4
Bodel L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35(10):1847-56.
5
Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001;28(9):1319-25.
6
Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406-16.
7
Garkavij M, Nickel M, Sjogreen-Gleisner K, Ljunberg M, Ohlsson T, Wingardh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumours: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084-92.
8
Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):92S-8S.
9
10. Heikkonen J, Mäenpää H, Hippeläinen E, Reijonen V, Tenhunen M. Effect of calculation method on kidney dosimetry in 177Lu-octreotate treatment. Acta Oncol. 2016;55(9-10):1069-76.
10
11. Ljunberg M, Celler A, Konijnenberg MW, Eckerman K, Dewaraja YK, Sjogreen-Gleisner K. MIRD pamphlet No. 26: Joint EANM/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151-62.
11
12. Bailey D, Hennessy T, Willowson K, Schembri G, Roach P, Snowdon G, et al. Quantitative biodistribution & kinetics of a new formulation of [Lu-177]-Octreotate. J Nucl Med. 2015;3:336.
12
13. Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Pavlakis N, et al. Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System. Asia Ocean J Nucl Med Biol. 2015;3(2):107-15.
13
14. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S-61S.
14
15. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023-7.
15
16. Willowson K, Bailey DL, Baldock C. Quantitative SPECT reconstruction using CT-derived corrections. Phys Med Biol. 2008;53(12):3099-112.
16
17. Jackson PA, Beauregard JM, Hofman MS, Kron T, Hogg A, Hicks RJ. An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. Med Phys. 2013;40(11):112503.
17
ORIGINAL_ARTICLE
Evaluation of the Reconstruction Parameters of Brain Dopamine Transporter SPECT Images Obtained by a Fan Beam Collimator: A Comparison with Parallel-hole Collimators
Objective(s): The purpose of this study was to examine the optimal reconstruction parameters for brain dopamine transporter SPECT images obtained with a fan beam collimator and compare the results with those obtained by using parallel-hole collimators.Methods: Data acquisition was performed using two SPECT/CT devices, namely a Symbia T6 and an Infinia Hawkeye 4 (device A and B) equipped with fan-beam (camera A-1 and B-1), low- and medium-energy general-purpose (camera A-2 and B-2), and low-energy high-resolution (camera A-3 and B-3) collimators. The SPECT images were reconstructed using filtered back projection (FBP) with Chang’sattenuation correction. However, the scatter correction was not performed. A pool phantom and a three-dimensional (3D) brain phantom were filled with 123I solution to examine the reconstruction parameters. The optimal attenuation coefficient was based on the visual assessment of the profile curve, coefficient of variation (CV) [%], and summed difference from the reference activity of the pool phantom. The optimal Butterworth filter for the 3D-brain phantom was also determined based on a visual assessment. The anthropomorphic striatal phantom was filled with 123I solution at striatum-to-background radioactivity ratios of 8, 6, 4, and 3. The specific binding ratio (SBR) of the striatum (calculated by the CT method) was used to compare the results with those of the parallel-hole collimators.Results: The optimal attenuation coefficients were 0.09, 0.11, 0.05, 0.05, 0.11, and, 0.10 cm-1 for cameras A-1, A-2, A-3, B-1, B-2, and B-3, respectively. The cutoff frequencies of the Butterworth filter were 0.32, 0.40, and 0.36 cycles/cm for camera A, and 0.46, 0.44, and 0.44 cycles/cm for camera B, respectively. The recovery rates of the SBRmean with camera A were 51.2%, 49.4%, and 45.6%, respectively. The difference was notstatistically significant. The recovery rates of the SBR with camera B were 59.2%, 50.7%, and 50.8%, respectively. Camera B-1 showed significantly high SBR values.Conclusion: As the findings indicated, the optimal reconstruction parameters differed according to the devices and collimators. The fan beam collimator was found to provide promising results with each device.
https://aojnmb.mums.ac.ir/article_10330_9026f9683e335228e93af11d4c4e9476.pdf
2018-07-01
120
128
10.22038/aojnmb.2018.10330
SPECT/CT
dopamine transporter
fan-beam collimator
Keishin
Morita
mrtkisn17@gmail.com
1
Division of Medical Quantum Science, Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
AUTHOR
Akira
Maebatake
xpcryk11@gmail.com
2
Division of Medical Quantum Science, Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
AUTHOR
Rina
Iwasaki
rn.iwsk918@gmail.com
3
Radiological Science Course, Department of Health Sciences, School of Medicine, Kyushu University, Fukuoka, Japan
AUTHOR
Yuki
Shiotsuki
pxsk1105@gmail.com
4
Radiological Science Course, Department of Health Sciences, School of Medicine, Kyushu University, Fukuoka, Japan
AUTHOR
Kazuhiko
Himuro
himuro@med.kyushu-u.ac.jp
5
Division of Radiology, Department of Medical Technology, Kyushu University Hospital, Fukuoka, Japan
AUTHOR
Shingo
Baba
sbaba127@radiol.med.kyushu-u.ac.jp
6
Department of Clinical Radiology, Kyushu University Hospital, Fukuoka, Japan
AUTHOR
Masayuki
Sasaki
msasaki@hs.med.kyushu-u.ac.jp
7
Division of Medical Quantum Science, Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
LEAD_AUTHOR
Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0. J Nucl Med. 2012;53(1):154-63.
1
Darcourt J, Booji J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37(2):443-50.
2
O’Sullivan JD, Lees AJ. Nonparkinsonian tremors. Clin Neuropharmacol. 2000;23(5):233-8.
3
Furukawa Y, Kish SJ. Dopa-responsive dystonia: recent advances and remaining issues to be addressed. Mov Disord. 1999;14(5):709-15.
4
Albanece A, Colosimo C, Lees AJ, Tonali P. The clinical diagnosis of multiple system atrophy presenting as pure Parkinsonism. Adv Neurol. 1996;69:393-8.
5
Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]-FP-CIT SPET in healthy volunteers. Eur J Nucl Med Mol Imaging. 2000;27(7):867-9.
6
Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry. 1986;49(8):853-60.
7
Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson’s disease. Arch Neurol. 1990;47(12):1290-8.
8
Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT- FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med. 1996;37(11):1760-5.
9
10. Eshuis SA, Maguire RP, Leender KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33(2):200-9.
10
11. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36(3):454-62.
11
12. Maebatake A, Sato M, Kagami R, Yamashita Y, Komiya I, Himuro K. et al. An anthropomorphic phantom study of brain dopamine transporter SPECT images obtained using different SPECT/CT devices and collimators. J Nucl Med Technol. 2015;43(1):41-6.
12
13. Maebatake A, Imamura A, Kodera Y, Yamashita Y, Himuro K, Baba S, et al. Evaluation of iterative reconstruction method and attenuation correction in brain dopamine transporter SPECT using an anthropomorphic striatal phantom. Asia Ocean J Nucl Med Biol. 2016;4(2):72-80.
13
14. Tsui BM, Gullberg GT, Edgerton ER, Gilland DR, Perry JR, McCartney WH. Design and clinical utility of a fan beam collimator for SPECT imaging of the head. J Nucl Med. 1986;27(6):810-9.
14
15. Kouris K, Clarke GA, Jarrit PH, Townsend CE, Thomas SN. Physical performance evaluation of the Toshiba GCA-9300A triple-headed. J Nucl Med. 1993;34(10):1778-89.
15
16. King MA, Mukherjee JM, Kӧnik A, Zubal IG, Dey J, Licho R. Design of a multi-pinhole collimator for I-123 DaTscan Imaging on dual-headed SPECT systems in combination with a fan-beam collimator. IEEE Trans Nucl Sci. 2016;63(1):90-7.
16
17. Iida H, Hori Y, Ishida K, Imabayashi E, Matsuda H, Takahashi M, et al. Three-dimensional brain phantom containing bone and grey matter structures with a realistic head contour. Ann Nucl Med. 2013;27(1):25-36.
17
18. Snay ER, Treves ST, Fahey FH. Improved quality of pediatric 123I-MIBG images with medium-energy collimators. J Nucl Med Technol. 2011;39(2):100-4.
18
19. Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BL, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32(9):1100-7.
19
20. Crespo C, Gallego J, Cot A, Falcón C, Bullich S, Pareto D, et al. Quantification of dopaminergic neurotransmission SPECT studies with 123I-labelled radioligands. A comparison between different imaging systems and data acquisition protocols using Monte Carlo simulation. Eur J Nucl Med Mol Imaging. 2008;35(7):1334-42.
20
21. Frouin V, Comtat C, Reilhac A, Grégoire MC. Correction of partial-volume effect for PET striatal imaging: fast implementation and study of robustness. J Nucl Med. 2002;43(12):1715-26.
21
22. Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with 123I SPECT. J Nucl Med. 2003;44(7):1184-93.
22
23. Buvat I, Soret M, Hapdey S, Riddell C, Benali H, Di Paola R. Respective importance of scatter, attenuation, collimator response and partial volume effect corrections for accurate quantification in 123I dopamine receptor imaging. IEEE Med Imaging Conf Record. 2000;2:13-5.
23
24. Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative disease: impact upon patient classification. Eur J Nucl Med Mol Imaging. 2006;33(9):1062-72.
24
25. Tossici-Bolt L, Hoffman SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33(12):1491-9.
25
26. Cot A, Falcón C, Crespo C, Sempau J, Pareto D, Bullich S, et al. Absolute quantification in dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J Nucl Med. 2005;46(9):1497-504.
26
ORIGINAL_ARTICLE
Development of an 123I-metaiodobenzylguanidine Myocardial Three-Dimensional Quantification Method for the Diagnosis of Lewy Body Disease
Objective(s): We recently developed a new uptake index method for 123I-metaiodobenzylguanidine (123I-MIBG) heart uptake measurements by using planar images (radioisotope angiography and planar image) for the diagnosis of Lewy body disease (LBD), including Parkinson’s disease (PD) and dementia with Lewy bodies(DLB). However, the diagnostic accuracy of the uptake index was approximately equal to that of the heart-to-mediastinum ratio (H/M) for the discrimination of the LBD and non-LBD patients. A simple and pain-free uptake index method using 123I-MIBG SPECT images by modifying the uptake index method may show better diagnostic accuracy than the planar uptake index method. We hypothesized that the development of a new uptake index method for the determination of 123I-MIBG using single-photon emission computed tomography (SPECT) imaging would provide a reliable and reproducible diagnostic tool for clinical application. Regarding this, the purpose of this study was to develop a new uptake index method with a simple protocol to determine 123I-MIBG uptake on SPECT.Methods: The 123I-MIBG input function was determined from the input counts of the pulmonary artery, assessed by analyzing the pulmonary artery time-activity curves. The 123I-MIBG output function was obtained from 123I-MIBG SPECT counts on the polar map. The uptake index was calculated through dividing the output function by the input function (SPECT uptake method). For the purpose of the study, 77 patients underwent 123I-MIBG SPECT, with an average of 31.5 min after clinical assessment and injection of the tracer. The H/M values, as well as planar and SPECT uptake indices were calculated, and then correlated with clinical features.Results: According to the results, values obtained for LBD were significantly lower than those for non-LBD in all analyses (P<0.01). The overlap of the H/M values between the LBD and non-LBD cases ranged from 2.06 to 2.50. Furthermore, the overlap in uptake index values between LBD and non-LBD cases in planar image analysis was 1.05-1.29.The SPECT uptake index method showed the least overlap of 1.23-1.25, with the highest value for LBD patients clearly distinguished from the lowest value for the non-LBD patients.Conclusion: The new 123I-MIBG SPECT quantification method, developed by the input counts of the pulmonary artery, clearly distinguished LBD from non-LBD. Therefore, this method may be appropriate for routine clinical study.
https://aojnmb.mums.ac.ir/article_10595_120cae6ca4b312e4840cfcbe90978702.pdf
2018-07-01
129
138
10.22038/aojnmb.2018.10595
Iodine-123 metaiodobenzylguanidine
Lewy body disease
Quantification
Single-photon emission tomography
Yoshito
Kamiya
kamiya951@yahoo.co.jp
1
Graduate School of Health Sciences, Kumamoto University
AUTHOR
Satoru
Ota
ospazzto2@gmail.com
2
Graduate School of Health Sciences, Kumamoto University
AUTHOR
Yuta
Tanaka
tanaka_yuta_volley@yahoo.co.jp
3
Graduate School of Health Sciences, Kumamoto University,
AUTHOR
Kosuke
Yamashita
kosuke.a.yamashita@fujifilm.com
4
Graduate School of Health Sciences, KChuo-ku, kumamoto 862-0976, Japan
AUTHOR
Akihiro
Takaki
akihiro-t@fmt.teikyo-u.ac.jp
5
Faculty of Fukuoka Medical Technology Teikyo University, 6-22, Misaki-Machi, Omuta-shi, Fukuoka 836-8505, Japan
AUTHOR
Shigeki
Ito
shigekii@kumamoto-u.ac.jp
6
Department of Medical Imaging, Faculty of Life Sciences, Kumamoto University, Kuhonji 4-24-1, Kumamoto 862-0796, Japan
LEAD_AUTHOR
Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson’s disease and related disorders: it can be a specific marker for Lewy body disease. Ann Nucl Med. 2004;18(6):453-61.
1
Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging. 2008;52(4):378-87.
2
King AE, Mintz J, Royall DR. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord. 2011;26(7):1218-24.
3
Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33(4):471-7.
4
Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18(1):82-9.
5
Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol. 2014;21(5):970-8.
6
Kamiya Y, Ota S, Okumiya S, Yamashita K, Takaki A, Ito S. Uptake index of 123I-metaiodobenzylguanidine myocardial scintigraphy for diagnosing Lewy body disease. Asia Ocean J Nucl Med Biol. 2017;5(1):37-43.
7
Chen J, Folks RD, Verdes L, Manatunga DN, Jacobson AF, Garcia EV. Quantitative I-123 mIBG SPECT in differentiating abnormal and normal mIBG myocardial uptake. J Nucl Cardiol. 2012;19(1):92-9.
8
Van der Veen BJ, Al Younis I, de Roos A, Stokkel MP. Assessment of global cardiac I-123 MIBG uptake and washout using volumetric quantification of SPECT acquisitions. J Nucl Cardiol. 2012;19(4):752-62.
9
10. Giorgetti A, Burchielli S, Positano V, Kovalski G, Quaranta A, Genovesi D, et al. Dynamic 3D analysis of myocardial sympathetic innervation: an experimental study using 123I-MIBG and a CZT camera. J Nucl Med. 2015;56(3):464-9.
10
11. Mu X, Hasegawa S, Yoshioka J, Maruyama A, Maruyama K, Paul AK, et al. Clinical value of lung uptake of iodine-123 metaiodobenzylguanidine (MIBG), a myocardial sympathetic nerve imaging agent, in patients with chronic heart failure. Ann Nucl Med. 2001;15(5):411-6.
11
12. Ofuji A, Mimura H, Yamashita K, Takaki A, Sone T, Ito S. Development of a simple non-invasive microsphere quantification method for cerebral blood flow using I-123-IMP. Ann Nucl Med. 2016;30(3):242-9.
12
13. Ofuji A, Nagaoka R, Yamashita K, Takaki A, Ito S. A simple non-invasive I-123-IMP autoradiography method developed by modifying the simple non-invasive I-123-IMP microsphere method. Asia Ocean J Nucl Med Biol. 2018;6(1):50-6.
13
14. Yamashita K, Uchiyama Y, Ofuji A, Mimura H, Okumiya S, Takaki A, et al. Fully automatic input function determination program for simple noninvasive (123)I-IMP microsphere cerebral blood flow quantification method. Phys Med. 2016;32(9):1180-5.
14
15. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. 1967. Neurology. 2001;57(10 Suppl 3):S11-26.
15
16. Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18(1):82-9.
16
17. Metz CE, Herman BA, Shen JH. Maximum-likelihood estimation of receiver operating (ROC) curves from continuously distributed data. Stat Med. 1998;17(9):1033-53.
17
18. Dorfman DD, Berbaum KS, Metz CE. ROC rating analysis: generalization to the population of readers and cases with the jackknife method. Invest Radiol. 1992;27(12):1099.
18
19. Masunaga S, Uchiyama Y, Ofuji A, Nagaoka R, Tomimatsu T, Iwata A, et al. Development of an automatic ROI setting program for input function determination in 99mTc-ECD non-invasive cerebral blood flow quantification. Phys Med. 2014;30(4):513-20.
19
20. Garcia EV, Van Train K, Maddahi J, Prigent F, Friedman J, Areeda J, et al. Quantification of rotational thallium-201 myocardial tomography. J Nucl Med. 1985;26(1):17-26.
20
21. El Fakhri G, Buvat I, Benali H, Todd-Pokropek A, Di Paola R. Relative impact of scatter, collimator response, attenuation, and finite spatial resolution corrections in cardiac SPECT. J Nucl Med. 2000;41(8):1400-8.
21
22. Patil HR, Bateman TM, McGhie AI, Burgett EV, Courter SA, Case JA, et al. Diagnostic accuracy of high-resolution attenuation-corrected Anger-camera SPECT in the detection of coronary artery disease. J Nucl Cardiol. 2014;21(1):127-34.
22
23. Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values and standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016;30(3):188-99.
23
ORIGINAL_ARTICLE
Validation of Optimum ROI Size for 123I-FP-CIT SPECT Imaging Using a 3D Mathematical Cylinder Phantom
Objective(s): The partial volume effect (PVE) of single-photon emission computed tomography (SPECT) on corpus striatum imaging is caused by the underestimation of specific binding ratio (SBR). A large ROI (region of interest) set using the Southampton method is independent of PVE for SBR. The present study aimed to determine the optimal ROI size with contrast and SBR for striatum images and validate the Southampton method using a three-dimensional mathematical cylinder (3D-MAC) phantom.Methods: We used ROIs sizes of 27, 36, 44, 51, 61, 68, and 76 mm for targets with diameters 40, 20, and 10 mm on reference and processed images reconstructed using the 3D-MAC phantom. Contrast values and SBR were compared with the theoretical values to obtain the optimal ROI size.Results: The contrast values in the ROI with diameters of 51 (target: 40 mm in diameter) and 44 (target: 20 mm in diameter) mm matched the theoretical values. However, this value did not correspond with the 10-mm-diameter target. The SBR matched the theoretical value with an ROI of > 44 mm in the 20-mm-diameter target;but, it was under- and overestimated under any other conditions.Conclusion: These results suggested that an ROI should be 4-2 folds larger than the target size without PVE, and that the Southampton method was remarkably accurate.
https://aojnmb.mums.ac.ir/article_10638_b61b11e9330e5009d04cba58581dadc5.pdf
2018-07-01
139
148
10.22038/aojnmb.2018.10638
specific binding ratio
partial volume effect
Southampton method
Hideo
Onishi
onisi@pu-hiroshima.ac.jp
1
Program in Health and Welfare Graduate School of Comprehensive Scientific Research
Prefectural university of Hiroshima
LEAD_AUTHOR
Takayuki
SAKAI
sak96@gmail.com
2
1-1, Sonekitamachi, Kokura-Minami-ku, Kitakyusyu, Fukuoka, 800-0296, Japan
AUTHOR
Osamu
SHIROMOTO
siromoto@pu-hiroshima.ac.jp
3
Program in Health and Welfare Graduate School of Comprehensive Scientific Research, Prefectural University of Hiroshima 1-1, Gakuenmachi, Mihara, Hiroshima, 723-0053, Japan
AUTHOR
Hizuru
Amijima
h-amijima@huhs.ac.jp
4
Department of Nursing,Hyogo University of Health Sciences
AUTHOR
1.Brucke T, Asenbaum S, Pirker W, Diamshidian S, Wenger S, Wober C, et al. Measurement of the dopamine degeneration in Parkinson’s disease with [123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24.
1
2.Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123 I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62(2):133-40.
2
3.Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med. 1998;39(11):1879-84.
3
4.Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brücke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm. 1998;105(10-12):1213-28.
4
5.McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305-13.
5
6.Benamer TS, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15:503-10.
6
7.Albert NL, Unterrainer M, Diemling M, Xiong G, Bartenstein P, Koch W, et al. Implementation of the European multicentre database of healthy controls for [(123)I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. Eur J Nucl Med Mol Imaging. 2016;43(7):1315-22.
7
8.Soret M, Koulibaly PM, Darcourt J, Buvat I. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification. Eur J Nucl Med Mol Imaging. 2006;33(9):1062-72.
8
9.David R, Koulibaly M, Benoit M, Garcia R, Caci H, Darcourt J, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction. Clin Neurol Neurosurg. 2008;110(1):19-24.
9
10.Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of 123-I-FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33(12):1491-9.
10
11.Tossici-Bolt L, Dickson JC, Sera T, de Nijs R, Bagnara MC, Jonsson C, et al. Calibration of gamma camera systems for a multicentre European (123)I-FP-CIT SPECT normal database. Eur J Nucl Med Mol Imaging. 2011;38(8):1529-40.
11
12.Buchert R, Kluge A, Tossici-Bolt L, Dickson J, Bronzel M, Lange C, et al. Reduction in camera-specific variability in [(123)I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. Eur J Nucl Med Mol Imaging. 2016;43(7):1323-36.
12
13.Fleming JS, Bolt L, Stratford JS, Kemp PM. The specific uptake size index for quantifying radiopharmaceutical uptake. Phys Med Biol. 2004;49(14):N227-34.
13
14.Onishi H, Motomura N, Takahashi M, Yanagisawa M, Ogawa K. A 3-diemnsional mathematic cylinder phantom for the evaluation of the fundamental performance of SPECT. J Nucl Med Technol. 2010;38(1):42-8.
14
15.Hirayama H. EGS4 shower display system (EGS4PICT), windows version 2.0. KEK Int. 1996;651:96-9.
15
16.Narita Y, Eberl S, Iida H, Hutton BF, Braun M, Nakamura T, et al. Monte Carlo and experimental evaluation of accuracy and noise properties of two scatter correction methods for SPECT. Phys Med Biol. 1996;41(11):2481-96.
16
17.Soret M, Koulibaly PM, Darcourt J, Hapdey S, Buvat I. Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT. J Nucl Med. 2003;44(7):1184-93.
17
18.Tossici-Bolt L, Dickson JC, Sera T, Booij J, Asenbaun-Nan S, Bagnara MC, et al. [123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. EJNMMI Phys. 2017;4(1):8.
18
19.Dickson JC, Tossici-Bolt L, Sera T, Booij J, Ziebell M, Morbelli S, et al. The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I] FP-CIT SPECT imaging. EJNMMI Res. 2017;7(1):10.
19
ORIGINAL_ARTICLE
Radiosynthesis of 11C-phenytoin Using a DEGDEE Solvent for Clinical PET Studies
Objective(s): Phenytoin is an antiepileptic drug that is used worldwide. The whole-body pharmacokinetics of this drug have been extensively studied using 11C-phenytoin in small animals. However, because of the limited production amounts that are presently available, clinical 11C-phenytoin PET studies to examine the pharmacokinetics of phenytoin in humans have not yet been performed. We aimed to establish a new synthesis method to produce large amounts of 11C-phenytoin to conduct human studies.Methods: 11C-methane was produced using an in-house cyclotron by the 14N (p, α) 11C nuclear reaction of 5 % of hydrogen containing 95 % of nitrogen gas. About 30 GBq of 11C-methane was then transferred to ahomogenization cell containing Fe2O3 powder mixed with Fe granules heated at 320 0C to yield 11C-phosgene. Xylene, 1,4-dioxane, and diethylene glycol diethyl ether (DEGDEE) were investigated as possible reaction solvents.Results: The ratio of 11C-phenytoin radioactivity to the total 11C radioactivity in the reaction vessel (reaction efficiency) was 7.5% for xylene, 11% for 1,4-dioxane, and 37% for DEGDEE. The synthesis time was within 45 min from the end of bombardment until obtaining the final product. The radioactivity produced was more than 4.1 GBq in 10 mL of saline at the end of synthesis. The specific activity of the product ranged from 1.7 to 2.2GBq/μmol. The quality of the 11C-phenytoin injection passed all criteria required for clinical use.Conclusion: The use of DEGDEE as a solvent enabled the production of a large amount of 11C-phenytoin sufficient to enable PET studies examining the human pharmacokinetics of phenytoin.
https://aojnmb.mums.ac.ir/article_10846_0227e645cfaa249ef313329f77b04ed9.pdf
2018-07-01
149
154
10.22038/aojnmb.2018.10846
PET
Radiosynthesis
11C-phenytoin
Radiopharmacy
Yasukazu
Kanai
ykanai@mi.med.osaka-u.ac.jp
1
Molecular Imaging in Medicine, Graduate school of medicine, Osaka University, Suita, Japan
AUTHOR
Yoshinori
Miyake
miyakeyoshinori@gmail.com
2
Department of Bio-Medical Imaging, National Cerebral and Cardiovascular Center Research Insititute.
AUTHOR
Jun
Hatazawa
hatazawa@tracer.med.osaka-u.ac.jp
3
Osaka University Graduate School of Medicine
LEAD_AUTHOR
Buchthal F, Svensmark O, Schller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Arch Neurol. 1960;2(6):624-30.
1
Noach EL, Woodbury DM, Goodman LS. Studies on the absorption, distribution, fate and excretion of 4-C14-labeled diphenyhydantoin, J Pharmacol Exp Therap. 1958;122(3):301-14.
2
Noach EL, Vanrees HV. Intestinal distribution of intravenously administered diphyenythydontoin in the rat. Arch Int Pharmacodyn Ther. 1964; 150:52-61.
3
Winstead MB, Parr SJ, Rogal MJ, Brockman PS, Lubcher R, Khentigan A, et al. Relationship of molecular structure to in vivo scintigraphic distribution patterns of carbon-11-labeled compound. 3. [11C] hydantoins. J Med Chem. 1976;19(2):279-86.
4
Stavchansky SA, Tilbur RS, McDonald JM, Ting CT, Kostenbauder HB. In vivo distribution of carbon-11 phenytoin and its major metabolite, and their use in scintigraphic imaging. J Nucl Med. 1978;19(8):936-41.
5
Emran AM, Boothe TE, Finn RD, Vora MM, Kothari PJ. Use of 11C as a tracer for studying the synthesis of radiolabelled compounds-II: 2-[11C]-5, 5-diphenylhydantoin from [11C] cyanide. Int J Radiat Appl Instrument A. 1986;37(10):1033-8.
6
Roeda D, Westera G. The synthesis of some 11C-labeled antiepileptic drugs with potential utility as radiopharmaceuticals: hydantoins and barbiturates. Int J Appl Radiat Isotopes. 1981;32(11):843-5.
7
Hasegawa Y, Kanai Y, Hasegawa S, Okamoto T, Matsui T, Shimosegawa E, et al. Evaluation of brain and whole-body pharmacokinetics of 11C-labeled diphenylhydantoin in rats by means of planar positron imaging system. Ann Nucl Med. 2008;22(4):301-7.
8
Baron JC, Roeda D, Munari C, Crouzel C, Chodkiewicz JP, Comar D. Brain regional pharmacokinetics of 11C-labeled diphenylhydantoin: positron emission tomography in humans. Neurology. 1983;33(5):580-5.
9
10. Nishijima K, Kuge Y, Seki K. Ohkura K. Motoki N. Nagatsu K, et al. A simplified and improved synthesis of [11C]phosgene with iron and iron (III) oxide. Nucl Med Biol. 2002;29(3):345-50.
10
11. EU/EMEA/CPMP: position paper on non-clinical safety studies to support clinical trials with a single microdose. London: The European Medicines Agency (EMEA), Evaluation of Medicines for Human Use, CPMP/SWP/2599/02; 2003.
11
12. FDA US. Guidance for industry, investigators and reviewers, exploratory IND studies, US Department of Health and Human Services. New York: FDA, CDER; 2006
12
13. Mochida I, Shimosegawa E, Kanai Y, Naka S, Matsunaga K, Isohashi K, et al. Whole-body distribution of donepezil as an acetylcholinesterase inhibitor after oral administration in normal human subjects: a 11c-donepezil PET study. Asia Ocean J Nucl Med Biol. 2017;5(1):3-9.
13
14. Takano K, Kinoshita M, Arita H, Okita Y, Chiba Y, Kagawa N, et al. Diagnostic and prognostic value of 11c-methionine PET for nonenhancing gliomas. Am J Neuroradiol. 2016;37(1):44-50.
14
ORIGINAL_ARTICLE
The Value of Technetium-99m Labeled Alpha-Melanocyte- Stimulating Hormone (99mTc-α-MSH) in Diagnosis of Primary and Metastatic Lesions of Malignant Melanoma
Objective(s): Malignant melanoma is the most lethal type of skin cancers with unfavorable prognosis. Alpha-MSH peptide analogues have a high affinity for melanocortine-1 (MC1) receptors on melanocytes overexpressing in malignant melanoma cells. Pre-clinical studies have shown promising results for radiolabeled MSH imaging in this malignancy. The purpose of this study is to assess the diagnostic value of 99mTc-α-MSHimaging in malignant melanoma.Methods: Twenty-one patients (13 men) with pathologically confirmed malignant melanoma with or without metastatic distribution were included in this study. 740-1110 MBq 99mTc-α-MSH was injected and whole body scans were performed 20, 120 and 240 minutes post injection and were assessed both qualitatively and semi-quantitatively using target (T) to background (BG) ratio.Results: The T/BG ratio for the primary tumor bed was 2.51±2.26, 2.56±2.48 and 1.92±1.79 minutes in the whole body scans 20, 120 and 240 minutes post injection, respectively. The sensitivity, specificity, negativeand positive predictive values were 75%, 80%, 50% and 92% for primary lesion and 25%, 100%, 68% and 100% for distant metastasis, respectively.Conclusion: 99mTc-α-MSH is a newly introduced agent for diagnosis of tumoral lesions in malignant melanoma. Our study showed a high sensitivity with this modality in primary lesions as well as lymph nodeinvolvements. However the detection rate was not high in distant metastasis. The preliminary results are promising especially as a new complementary imaging method in management of malignant melanoma.
https://aojnmb.mums.ac.ir/article_10721_2847c09e8a4a7d8b21ec0ed642ce117b.pdf
2018-07-01
155
160
10.22038/aojnmb.2018.30101.1204
Malignant melanoma
99mTc-α-MSH
Melanocortine-1 receptor
Melanocyte stimulating hormone
Radiolabeled peptide
Saeed
Farzanefar
farzanehfar@tums.ac.ir
1
Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Rahman
Etemadi
etemadirahman@gmail.com
2
Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad
Shirkhoda
mshirkhoda@yahoo.com
3
Department of General Surgery, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Habibollah
Mahmoodzadeh
اmahmoodzadeh@tums.ac.ir
4
Department of General Surgery, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mostafa
Erfani
mgandomkar@aeoi.org.ir
5
Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
AUTHOR
Babak
Fallahi
bfallahi@sina.tums.ac.ir
6
Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mehrshad
Abbasi
meabbasi@tums.ac.ir
7
Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Narjess
Ayati
ayatin871@mums.ac.ir
8
Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Arman
Hassanzadeh-Rad
arman.h.rad@gmail.com
9
Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad
Eftekhari
meftekhari@yahoo.com
10
Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Davood
Beiki
beikidav@sina.tums.ac.ir
11
Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Erdei E, Torres SM. A new understanding in the epidemiology of melanoma. Expert Rev Anticancer Ther. 2010;10(11):1811-23.
1
Bandarchi B, Ma L, Navab R, Seth A, Rasty G. From melanocyte to metastatic malignant melanoma. Dermatol Res Pract. 2010;2010:583748.
2
Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7(4):572-6.
3
Singnurkar A, Wang J, Joshua AM, Langer DL, Metser U. 18F-FDG-PET/CT in the staging and management of melanoma: a prospective multicenter ontario PET registry study. Clin Nucl Med. 2016;41(3):189-93.
4
Dimitrakopoulou-Strauss A, Strauss LG, Burger C. Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis. J Nucl Med. 2001;42(2):248-56.
5
Liu L, Xu J, Yang J, Feng C, Miao Y. Imaging human melanoma using a novel Tc-99m-labeled lactam bridge-cyclized alpha-MSH peptide. Bioorg Med Chem Lett. 2016;26(19):4724-8.
6
Shamshirian D, Erfani M, Beiki D, Fallahi B, Shafiei M. Development of a (99m)Tc-labeled lactam bridge-cyclized alpha-MSH derivative peptide as a possible single photon imaging agent for melanoma tumors. Ann Nucl Med. 2015;29(8):709-20.
7
Miao Y, Benwell K, Quinn TP. 99mTc- and 111In-labeled alpha-melanocyte-stimulating hormone peptides as imaging probes for primary and pulmonary metastatic melanoma detection. J Nucl Med. 2007;48(1):73-80.
8
Guo H, Miao Y. Cu-64-labeled lactam bridge-cyclized α-MSH peptides for PET imaging of melanoma. Mol Pharm. 2012;9(8):2322-30.
9
10. Guo H, Yang J, Gallazzi F, Miao Y. Effects of the amino acid linkers on the melanoma-targeting and pharmacokinetic properties of 111In-labeled lactam bridge-cyclized alpha-MSH peptides. J Nucl Med. 2011;52(4):608-16.
10
11. Guo H, Gallazzi F, Miao Y. Gallium-67-labeled lactam bridge-cyclized alpha-MSH peptides with enhanced melanoma uptake and reduced renal uptake. Bioconjug Chem. 2012;23(6):1341-8.
11
12. Guo H, Miao Y. Melanoma targeting property of a Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide. Bioorg Med Chem Lett. 2013;23(8):2319-23.
12
13. Guo H, Miao Y. Introduction of an 8-aminooctanoic acid linker enhances uptake of 99mTc-labeled lactam bridge-cyclized α-MSH peptide in melanoma. J Nucl Med. 2014;55(12):2057-63.
13
14. Liu L, Xu J, Yang J, Feng C, Miao Y. Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. Bioorg Med Chem Lett. 2017;27(22):4952-5.
14
15. Vreugdenburg TD, Ma N, Duncan JK, Riitano D, Cameron AL, Maddern GJ. Comparative diagnostic accuracy of hepatocyte-specific gadoxetic acid (Gd-EOB-DTPA) enhanced MR imaging and contrast enhanced CT for the detection of liver metastases: a systematic review and meta-analysis. Int J Colorectal Dis. 2016;31(11):1739-49.
15
16. Krug B, Dietlein M, Groth W, Stützer H, Psaras T, Gossmann A, et al. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods. Acta Radiol. 2000;41(5):446-52.
16
17. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227(5):764-9.
17
ORIGINAL_ARTICLE
Feasibility of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic stem cell transplantation: a study protocol
Objective(s): High-risk neuroblastoma is a childhood cancer with poorprognosis despite modern multimodality therapy. Internal radiotherapy using131I-metaiodobenzylguanidine (MIBG) is effective for treating the disease even if it isresistant to chemotherapy. The aim of this study is to evaluate the safety and efficacyof 131I-MIBG radiotherapy combined with myeloablative high-dose chemotherapyand hematopoietic stem cell transplantation.Methods: Patients with high-risk neuroblastoma will be enrolled in this study. A totalof 8 patients will be registered. Patients will receive 666 MBq/kg of 131I-MIBG andafter safety evaluation will undergo high-dose chemotherapy and hematopoietic stemcell transplantation. Autologous and allogeneic stem cell sources will be accepted.After engraftment or 28 days after hematopoietic stem cell transplantation, the safetyand response will be evaluated.Conclusion: This is the first prospective study of 131I-MIBG with high-dosechemotherapy and hematopoietic stem cell transplantation in Japan. The results willbe the basis of a future nationwide clinical trial.
https://aojnmb.mums.ac.ir/article_10769_d6ef75df32736d417d90d27453c3750d.pdf
2018-07-01
161
166
10.22038/aojnmb.2018.29845.1203
131I-MIBG
Neuroblastoma
Hematopoietic stem cell transplantation
Prospective study protocol
Raita
Araki
raraki@staff.kanazawa-u.ac.jp
1
Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan
LEAD_AUTHOR
Ryosei
Nishimura
ryosein@staff.kanazawa-u.ac.jp
2
Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan
AUTHOR
Anri
Inaki
henri@staff.kanazawa-u.ac.jp
3
Department of Nuclear Medicine, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan
AUTHOR
Hiroshi
Wakabayashi
wakabayashi@staff.kanazawa-u.ac.jp
4
Department of Nuclear Medicine, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan
AUTHOR
Yasuhito
Imai
imaiya@staff.kanazawa-u.ac.jp
5
Innovative Clinical Research Center, Kanazawa University, Japan
AUTHOR
Yoshikazu
Kuribayashi
kuribayashi@staff.kanazawa-u.ac.jp
6
Innovative Clinical Research Center, Kanazawa University, Japan
AUTHOR
Kenichi
Yoshimura
keyoshim@staff.kanazawa-u.ac.jp
7
Innovative Clinical Research Center, Kanazawa University, Japan
AUTHOR
Toshinori
Murayama
toshi@staff.kanazawa-u.ac.jp
8
Innovative Clinical Research Center, Kanazawa University, Japan
AUTHOR
Seigo
Kinuya
kinuya@med.kanazawa-u.ac.jp
9
Department of Nuclear Medicine, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Japan
AUTHOR
Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106-20.
1
Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2011.
2
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27(2):289-97.
3
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008-17.
4
Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA, et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group “Survey” 1982-1992. Eur J Cancer. 2000;36(7):901-8.
5
London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group Project. J Clin Oncol. 2011;29(24):3286-92.
6
Streby KA, Shah N, Ranalli MA, Kunkler A, Cripe TP. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131 I-mIBG therapy. Pediatr Blood Cancer. 2015;62(1):5-11.
7
Matthay KK, Desantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, et al. Phase I dose escalation of 31 1-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma. J Clin Oncol. 1998;16(1):229-36.
8
Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, et al. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial. J Nucl Med. 2012;53(7):1155-63.
9
10. DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, et al. Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004;22(12):2452-60.
10
11. Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, et al. 131I-Metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study. Biol Blood Marrow Transplant. 2015;21(4):673-81.
11
12. Kinuya S, Yoshinaga K, Higuchi T, Jinguji M, Kawamoto H, Kurihara H. Draft guideline regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors Drafting Committee for Guideline of Radiotherapy with 131I-MIBG, Committee for Nuclear Oncology and Immunology, The Japanese Society of Nuclear Medicine. Kaku Igaku. 2015;52(1):1-15.
12
13. Giammarile F, Chiti A, Lassmann M, Brans B, Flux G. EANM procedure guidelines for131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35(5):1039-47.
13
14. Mazloom A, Louis CU, Nuchtern J, Kim E, Russell H, Allen-Rhoades W, et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 2014;90(4):858-62.
14
15. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13- cis -retinoic acid. N Engl J Med. 1999;341(16):1165-73.
15
16. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14(10):999-1008.
16
17. Ladenstein R, Pötschger U, Pearson AD, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18(4):500-14.
17
18. Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK. Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG). Eur J Cancer. 2015;51(16):2465-72.
18
19. Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25(9):1054-60.
19
20. Clement SC, van Rijn RR, van Eck-Smit BL, van Trotsenburg AS, Caron HN, Tytgat GA, et al. Long-term efficacy of current thyroid prophylaxis and future perspectives on thyroid protection during 131I-metaiodobenzylguanidine treatment in children with neuroblastoma. Eur J Nucl Med Mol Imaging. 2015;42(5):706-15.
20
21. Willems L, Waer M, Billiau AD. The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms. Pediatr Blood Cancer. 2014;61(12):2151-7.
21
22. Lee JW, Kang ES, Sung KW, Yi E, Lee SH, Yoo KH, et al. Incorporation of high-dose131I-metaiodobenzylguanidine treatment into killer immunoglobulin-like receptor/HLA-ligand mismatched haploidentical stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer. 2017;64(6):1-8.
22
ORIGINAL_ARTICLE
Sagliker Syndrome in a Patient with Secondary Hyperparathyroidism and Chronic Renal Insufficiency: A Case Report
Sagliker syndrome is a rare form of renal osteodystrophy resulted from untreated secondary hyperparathyroidism. It is described by severe skeletal deformities, high level of PTH in patients with chronic renal failure, and deformed face. This paper reports a 44-year-old male patient with the mentioned characteristics. In addition to the unique clinical features, high levels of ALP and PTH hormones encouraged us to search for syndrome-like a disease, which clinically and paraclinically matched the Sagliker syndrome.This case highlights the importance of clinicians’ attention for earlymonitoring and appropriate treatment as it is shown to be effective in preventing irreversible complications such as soft tissue and bone abnormalities and cardiovascular impairment in patients with Sagliker syndrome. Therefore, considering the syndrome isrecommended as one of the diagnostic hypothesis in young patients with renal insufficiency, secondary hyperparathyroidism, and skeletal deformities.
https://aojnmb.mums.ac.ir/article_10567_1b736252d6647556439ece3fd62f64e4.pdf
2018-07-01
167
170
10.22038/aojnmb.2018.10567
chronic renal failure
renal osteodystrophy
Sagliker syndrome
secondary hyperparathyroidism
Skeletal Deformity
Sara
Shakeri
shakeris951@mums.ac.ir
1
Nuclear Medicine Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Soroush
Zarehparvar Moghadam
zarrehparvars951@mums.ac.ir
2
Nuclear Medicine Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Ramin
Sadeghi
sadeghir@mums.ac.ir
3
Nuclear Medicine Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Narjess
Ayati
ayatin@mums.ac.ir
4
Nuclear Medicine Research Center, Mashhad University of Medical Science
LEAD_AUTHOR
Sagliker Y, Balal M, Sagliker Ozkaynak P, Paydas S, Sagliker C, Sabit Sagliker H, et al. Sagliker syndrome: uglifying human face appearance in late and severe secondary hyperparathyroidism in chronic renal failure. Semin Nephrol. 2004;24(5):449-55.
1
Chen XH, Shen B, Zou JZ, Ding XQ, Liu ZH, Lv W, et al. Clinical status of Sagliker syndrome: a case report and literature review. Ren Fail. 2014;36(5):800-3.
2
Mohebi-Nejad A, Gatmiri SM, Abooturabi SM, Hemayati R, Mahdavi-Mazdeh M. Diagnosis and treatment of Sagliker syndrome; a case series from Iran. Iran J Kidney Dis. 2014;8(1):76-80.
3
Yavascan O, Kose E, Alparslan C, Sirin Kose S, Bal A, Kanik A, et al. Severe renal osteodystrophy in a pediatric patient with end-stage renal disease: Sagliker syndrome? J Ren Nutr. 2013;23(4):326-30.
4
Lopes ML, Albuquerque AF, Germano AR, Queiroz LM, Miguel MC, Silveira EJ. Severe maxillofacial renal osteodystrophy in two patients with chronic kidney disease. Oral Maxillofac Surg. 2015;19(3):321-7.
5
Yildiz I, Sagliker Y, Demirhan O, Tunc E, Inandiklioglu N, Tasdemir D, et al. International evaluation of unrecognizably uglifying human faces in late and severe secondary hyperparathyroidism in chronic kidney disease. sagliker syndrome. A unique catastrophic entity, cytogenetic studies for chromosomal abnormalities, calcium-sensing receptor gene and GNAS1 mutations. Striking and promising missense mutations on the GNAS1gene exons 1, 4, 10, 4. J Ren Nutr. 2012;22(1):157-61.
6
Tunç E, Demirhan O, Sağliker Y, Yildiz İ, Paylar N, Güzel Aİ. Chromosomal findings, and sequence analysis of target exons of calcium-sensing receptor (CaSR) gene in patients with Sagliker syndrome. Turk J Med Sci. 2017;47(1):13-21.
7
Mejía Pineda A, Aguilera ML, Meléndez HJ, Lemus JA, Peñalonzo MA. Sagliker syndrome in patients with secondary hyperparathyroidism and chronic renal failure: Case report. Int J Surg Case Rep. 2015;8C:127-30.
8
Grzegorzewska AE, Kaczmarek-lek V. A case of severe long-term secondary hyperparathyroidism (Sagliker syndrome) in a patient treated with intermittent hemodialysis. Nefrol Dializoter Polska. 2011;15:57-60.
9
10. Wu W, Qian L, Chen X, Ding B. A case of Sagliker syndrome and literature review. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2014;39(10):1100-4.
10
11. Sagliker Y, Acharya V, Golea O, Sabry A, Bali M, Eyupoglu K, et al. Is survival enough for quality of life in Sagliker Syndrome-uglifying human face appearances in chronic kidney disease? J Nephrol. 2008;21(Suppl 13):S134-8.
11
ORIGINAL_ARTICLE
Utility of 99mTc-Sestamibi SPECT/CT in the Early Localization of Metastatic Parathyroid Carcinoma
Parathyroid carcinoma is very rare, with only a few documented cases. Hence, metastatic lesions are infrequently documented on scintigraphic imaging. We present a case of a 63-year-old female presenting with elevated serum levels of ionized calcium and parathyroid hormone (PTH) who was referred to our department for a parathyroid scan with SPECT/ CT. Parathyroid scintigraphy showed a focus of increased 99mTc-sestamibi uptake corresponding to a solid mass with calcification in the inferior pole of the right thyroid lobe; tracer retention was noted on delayed images. Incidentally, focal uptake was also seen in a soft tissue mass on the 7th right rib. The patient soon underwent total thyroidectomy, with biopsy revealing parathyroid carcinoma on the right lobe. A bone scan done 7 months after surgery confirmed the presence of metastatic bone disease. The concomitant detection of intrathyroidal and extrathyroidal sestamibiavid masses on parathyroid scintigraphy should increase clinical suspicion of a metastatic process from parathyroid carcinoma.
https://aojnmb.mums.ac.ir/article_10183_00a21d1ee413ff4349db1d29f0e6748e.pdf
2018-07-01
171
178
10.22038/aojnmb.2017.27484.1190
Parathyroid carcinoma
SPECT/CT
99mTc-sestamibi
Patrick Earl
Fernando
patrixx.three@gmail.com
1
Department of Nuclear Medicine and PET Center St. Luke's Medical Center Bonifacio Global City, Taguig, Philippines
LEAD_AUTHOR
Patricia
Bautista
pattybautista@gmail.com
2
Department of Nuclear Medicine and PET Center St. Luke's Medical Center Bonifacio Global City, Taguig, Philippines
AUTHOR
Elgazzar AH, Alenezi SA. Parathyroid gland. In: Elgazzar AH, editor. The pathophysiologic basis of nuclear medicine. 3rd ed. Switzerland: Springer International Publishing; 2015. P. 283-8.
1
Ahmetbegović N, Suljagić N, Katica V. Significance of parathyroid scintigraphy and correlation of findings with parathyroid hormone values in patients undergoing hemodialysis. Med Glas (Zenica). 2017;14(2):158-63.
2
Ziessman HA, O’Malley JP, Thrall JH. Endocrine System. The requisites: nuclear medicine. 4th ed. Philadelphia: Elsevier Health Sciences; 2014. P. 90-2.
3
Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13(1):11-23.
4
Digonnet A, Carlier A, Willemse E, Quiriny M, Dekeyser C, de Saint Aubain N, et al.Parathyroid carcinoma: a review with three illustrative cases. J Cancer. 2011;2:532-7.
5
Givi B, Shah JP. Parathyroid carcinoma. Clin Oncol (R Coll Radiol). 2010;22(6):498-507.
6
Iacobone M, Lumachi F, Favia G. Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol. 2004;88(4):223-8.
7
Ruan M, Shen Y, Zhang H, Li M, Chen L. Bone metastasis from parathyroid carcinoma mon-avid for 99mTc-MIBI, 99mTc-MDP, and 18F-FDG. J Nucl Med Radiat Ther. 2014;5(1):165-8.
8
Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab. 2001;86(2):485-93.
9
10. Choi JH, Kim KJ, Lee YJ, Kim SH, Kim SG, Jung KY, et al. Primary hyperparathyroidism with extensive brown tumors and multiple fractures in a 20-year-old woman. Endocrinol Metab. 2015;30(4):614-9.
10
11. Evangelista L, Sorgato N, Torresan F, Boschin IM, Pennelli G, Saladini G, et al. FDG-PET/CT and parathyroid carcinoma: review of literature and illustrative case series. World J Clin Oncol. 2011;2(10):348-54.
11
ORIGINAL_ARTICLE
Adrenocortical Oncocytic Carcinoma and Papillary Thyroid Carcinoma Incidentally Detected in an Asymptomatic Patient by F-18 FDG PET/CT
F-18 FDG is the most widely used tracer in molecular imaging and it is applied for many purposes mainly in malignant diseases. Incidental finding are common in FDG-PET/CT imaging and includes benign and malignant lesions. Among the rare tumors , adrenal oncocytomas are uncommon findings and incidental findings of thyroid malignancies are not rare. Oncocytoma is a rare adrenocortical tumor and majority of bulky adrenal tumors are benign with uncertain incident of malignancy. In this study, we are reporting a 37-year-old man with two incidental malignancies detected by FDG-PET-CT. He has no symptoms has no blood and hormonal abnormalities. The scan demonstrated intense heterogeneous FDG uptake within the bulky oval shaped lesion in the left adrenal gland. Accordingly, open adrenalectomy was performed and diagnosis of adrenocortical carcinoma oncocytic type was established. Furthermore, a focal FDG uptake was identified in the right thyroid lobe and histopathology findings were consistent with well-differentiated papillary thyroid cancer. FDG plays a great role in identifying primary rare lesions and also detection of incidental findings at unexpected sites.
https://aojnmb.mums.ac.ir/article_10845_00609beb161769849487c215ee60fc24.pdf
2018-07-01
179
185
10.22038/aojnmb.2018.10845
F-18 FDG
adrenal mass
adrenocortical carcinoma
thyroid carcinoma, adrenal oncocytoma
Batool
Al Balooshi
curie2000@hotmail.com
1
Dubai nuclear Medicine and Molecular imaging Center, Dubai Hospital, Dubai Health Authority, Dubai-UAE
LEAD_AUTHOR
Shabna
Miyanath
smiyanath@dha.gov.ae
2
Dubai nuclear Medicine and Molecular imaging Center, Dubai Hospital, Dubai Health Authority, Dubai-UAE
AUTHOR
Amr
Elhennawy
amelhennawy@dha.gov.ae
3
Dubai nuclear Medicine and Molecular imaging Center, Dubai Hospital, Dubai Health Authority, Dubai-UAE
AUTHOR
yaser
Saeedi
yasaeedi@dha.gov.ae
4
Department of Urology, Dubai Hospital, Dubai Health Authority, Dubai-UAE
AUTHOR
Syed Hammad
Tirmazy
shtirmazy@dha.gov.ae
5
Department of Oncology, Dubai Hospital, Dubai Health Authority, Dubai-UAE
AUTHOR
Muhammed
Muhasin
mmuhasin@dha.gov.ae
6
Dubai Nuclear Medicine and Molecular imaging Center, Dubai Hospital, Dubai Health Authority, Dubai-UAE
AUTHOR
Bhavna
Ray
bray@dha.gov.ae
7
Dubai nuclear Medicine and Molecular imaging Center, Dubai Hospital, Dubai Health Authority, Dubai-UAE
AUTHOR
Mouza
Al Sharhan
maalsharhan@dha.gov.ae
8
Department of Pathology and Genetics, Dubai Hospital, Dubai Health Authority, Dubai, UAE
AUTHOR
Hassan
Hotait
hyhotait@dha.gov.ae
9
Department of Pathology and Genetics, Dubai Hospital, Dubai Health Authority, Dubai, UAE
AUTHOR
Yamina
Houcinat
yhoucinat@dha.gov.ae
10
Department of Pathology and genetics, Dubai hospital, Dubai Heath Authority, Dubai, UAE
AUTHOR
Tasnim
Keloth
trkeloth@dha.gov.ae
11
Department of Pathology and Genetics, Dubai Hospital, Dubai Health Authority, Dubai, UAE
AUTHOR
Hong Y, Hao Y, Hu J, Xu B, Shan H, Wang X. Adrenocortical oncocytoma: 11 case reports and review of the literature. Medicine. 2017;96(48):e8750.
1
Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001;42(12):1795-9.
2
Launay N, Silvera S, Tenenbaum F, Groussin L, Tissier F, Audureau E, et al. Value of 18-F-FDG PET/CT and CT in the diagnosis of indeterminate adrenal masses. Int J Endocrinol. 2015;2015:213875.
3
Agrawal K, Weaver J, Ul-Hassan F, Jeannon JP, Simo R, Carroll P, et al. Incidence and significance of incidental focal thyroid uptake on 18F-FDG PET study in a large patient cohort: retrospective single-centre experience in the United Kingdom. Eur Thyroid J. 2015;4(2):115-22.
4
Oishi S, Sasaki M, Sato T, Isogai M. Coexistence of MEN 2A and papillary thyroid carcinoma and a recurrent pheochromocytoma 23 years after surgery: report of a case and a review of the Japanese literature. Jpn J Clin Oncol. 1995;25(4):153-8.
5
Bugalho MJ, Silva AL, Domingues R. Coexistence of paraganglioma/pheochromocytoma and papillary thyroid carcinoma: a four-case series analysis. Fam Cancer. 2015;14(4):603-7.
6
Sisson JC, Giordano TJ, Avram AM. Three endocrine neoplasms: an unusual combination of pheochromocytoma, pituitary adenoma, and papillary thyroid carcinoma. Thyroid. 2012;22(4):430-6.
7
Wanta SM, Basina M, Chang SD, Chang DT, Ford JM, Greco R, et al. A rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male. Rare Tumors. 2011;3(4):e45.
8
Podetta M, Pusztaszeri M, Toso C, Procopiou M, Triponez F, Sadowski SM. Oncocytic adrenocortical neoplasm with concomitant papillary thyroid cancer. Front Endocrinol. 2017;8:384.
9
10. Ginzburg S, Reddy M, Veloski C, Sigurdson E, Ridge JA, Azrilevich M, et al. Papillary thyroid carcinoma metastases presenting as ipsilateral adrenal mass and renal cyst. Urol Case Rep. 2015;3(6):221-2.
10
11. Koutkia P, Safer JD. Adrenal metastasis secondary to papillary thyroid carcinoma. Thyroid. 2001;11(11):1077-9.
11
12. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med. 2001; 42(12):1795-9.
12
13. Launay N, Silvera S, Tenenbaum F, Groussin L, Tissier F, Audureau E, et al. Value of 18-F-FDG PET/CT and CT in the diagnosis of indeterminate adrenal masses. Int J Endocrinol. 2015;2015:213875.
13
14. Bertagna F, Treglia G, Piccardo A, Giovannini E, Bosio G, Biasiotto G, et al. F18-FDG-PET/CT thyroid incidentalomas: a wide retrospective analysis in three Italian centres on the significance of focal uptake and SUV value. Endocrine. 2013;43(3):678-85.
14
15. Algin E, Uner A, Akdemir UO, Gumusay O, Kapucu O, Ozet A. The assessment of incidental thyroid lesions on 18F-fluorodeoxyglucose positron emission tomography/computed tomography: A single center experience. J Oncol Sci. 2017;3(2):57-61.
15
16. Nockel P, Millo C, Keutgen X, Klubo-Gwiezdzinska J, Shell J, Patel D, et al. The rate and clinical significance of incidental thyroid uptake as detected by gallium-68 DOTATATE positron emission tomography/computed tomography. Thyroid. 2016;26(6):831-5.
16
ORIGINAL_ARTICLE
Letter to the Editor
No Abstract is available
https://aojnmb.mums.ac.ir/article_10725_a90354d55d9426fe410eb7974f0a6e77.pdf
2018-07-01
186
186
10.22038/aojnmb.2018.10725
harmonization
digital reference object
QIBA
Tadaki
Nakahara
nakahara@rad.med.keio.ac.jp
1
Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
LEAD_AUTHOR
Tsutsui Y, Awamoto S, Himuro K, Umezu Y, Baba S, Sasaki M. Characteristics of smoothing filters to achieve the guideline recommended positron emission tomography image without harmonization. Asia Ocean J Nucl Med Biol. 2018;6(1):15-23.
1
Nakahara T, Daisaki H, Yamamoto Y, Iimori T, Miyagawa K, Okamoto T, et al. Use of a digital phantom developed by QIBA for harmonizing SUVs obtained from the state-of-the-art SPECT/CT systems: a multicenter study. EJNMMI Res. 2017;7(1):53.
2
Pierce LA 2nd, Elston BF, Clunie DA, Nelson D, Kinahan PE. A digital reference object to analyze calculation accuracy of PET standardized uptake value. Radiology. 2015;277(2):538-45.
3
ORIGINAL_ARTICLE
Response to the letter to editor
No Abstract is available
https://aojnmb.mums.ac.ir/article_10746_b0974b85d28e0a8d4089051e09909efb.pdf
2018-07-01
187
188
10.22038/aojnmb.2018.10746
FDG PET
Smoothing filter
SUV
Yuji
Tsutsui
yuji1006@med.kyushu-u.ac.jp
1
Division of Radiology, Department of Medical Technology, Kyushu University Hospital, Fukuoka, Japan
LEAD_AUTHOR
Pierce LA 2nd, Elston BF, Clunie DA, Nelson D, Kinahan PE. A digital reference object to analyze calculation accuracy of PET standardized uptake value. Radiology. 2015;277(2):538-45.
1
Kinahan P, Pierce L, Elston B, Clunie D, Nelson D. An FDG-PET/CT digital reference object for testing ROI and SUV calculations. J Nucl Med. 2012;53(Supple 1):607.
2
Harrison RL, Elston BF, Byrd DW, Alessio AM, Jacobs J, Rockne RC, et al. A digital reference object for the 3D Hoffman brain phantom for characterization of PET neuroimaging quality. Nuclear Science Symposium and Medical Imaging Conference, Seoul, South Korea; 27 Oct.-2 Nov. 2013.
3
Akamatsu M, Yamashita Y, Akamatsu G, Tsutsui Y, Ohya N, Nakamura Y, et al. Influences of reconstruction and attenuation correction in brain SPECT images obtained by the hybrid SPECT/CT device: evaluation with a 3-dimensional brain phantom. Asia Oceania J Nucl Med Biol. 2014;2(1):24-9.
4
Digital reference object. Quantitative Imaging Biomarkers Alliance (QIBA). Available at: URL: http://depts.washington.edu/petctdro/; 2018.
5
Dikaios N, Izquierdo-Garcia D, Graves MJ, Mani V, Fayad ZA, Fryer TD. MRI-based motion correction of thoracic PET initial comparison of acquisition protocols and correction strategies suitable for simultaneous PET MRI systems. Eur Radiol. 2012;22(2):439-46
6
Lasnon C, Desmonts C, Quak E, Gervais R, Do P, Dubos-Arvis C, et al. Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(7):985-96.
7
Kelly MD, Declerck JM. SUVref: reducing reconstruction-dependent variation in PET SUV. EJNMMI Res. 2011;1(1):16.
8